The injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.
Wegovy has been approved for use as a heart disease prevention medication, the FDA announced on Friday.The injectable semaglutide — originally approved for weight loss for certain patients — is now also indicated to reduce the risk of cardiovascular death, heart attack and stroke in adults who have cardiovascular disease and are either overweight or obese, the announcement stated.
"The FDA’s approval is a step in the right direction toward battling the "bias and stigma" around these medications, she said."Significantly reducing the risk of cardiac disease in patients who are at a higher risk is incredibly important to both patients and clinicians," Pratt went on. "We hope that with this indication, these patients who unfortunately may not have had coverage for these medications before will soon find them covered.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves Wegovy to reduce heart attack and stroke riskBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Les mer »
FDA approves Wegovy for lowering heart attack and stroke risk in overweight patientsThe popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, the FDA said.
Les mer »
FDA approves Wegovy to reduce heart attack and stroke riskThe U.S. Food and Drug Administration approved a label change that expands the use of the drug in Wegovy. It was previously approved to treat obesity.
Les mer »
FDA approves weight-loss drug Wegovy to reduce heart-disease risksThe FDA approved the weight-loss drug Wegovy as a treatment to reduce cardiovascular risk in adults who are overweight, the first approval of its kind.
Les mer »
Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drugWegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.
Les mer »
FDA approves Wegovy for cardiovascular diseaseThe FDA on Friday approved Wegovy to lower the risk of cardiovascular death for people who are obese or overweight, a first of its kind classification.
Les mer »